Physician profile
Zial Salem
NPI 1679538052
$1,609.30
in general payments reported to CMS, 2019-2025
15 companies · $313 in 2025
The $313 reported for 2025 was less than what a typical Hepatology provider received nationally (typical 2025 total: $981).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $381 · 2020: $83.01 · 2021: $320 · 2022: $55.18 · 2023: $225 · 2024: $234 · 2025: $313.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $771.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $770.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $590.27 | 2019-2025 | Xifaxan, Trulance |
| Abbvie INC. | $431.81 | 2019-2025 | |
| Pfizer INC. | $168.48 | 2023-2025 | |
| Gilead Sciences, INC. | $100.38 | 2019-2023 | |
| Ucb, INC. | $55.07 | 2019-2020 | |
| Ardelyx, INC. | $49.15 | 2024 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $46.18 | 2019 | |
| Merck Sharp & Dohme LLC | $39.30 | 2019-2021 | |
| Allergan, INC. | $25.40 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $23.34 | 2022 | |
| Madrigal Pharmaceuticals | $20.25 | 2025 | Rezdiffra |
| Celgene Corporation | $17.46 | 2023 | Zeposia |
| Novo Nordisk INC | $15.08 | 2025 | Wegovy |
| Ironwood Pharmaceuticals, INC | $15.08 | 2019 | |
| Janssen Biotech, INC. | $12.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zial Salem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.